CG-3-246

CG-3-246 is a dual inhibitor of FLT3/BCL-2, with the Kds of 63 and 4.25 nM, respectibely. CG-3-246 plays an important role in acute myeloid leukemias research[1].

Product Specifications

UNSPSC

12352005

Target

Bcl-2 Family; FLT3

Related Pathways

Apoptosis; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

O=C(C1=NC(CC)=C(NC2CCOCC2)N=C1NC3=CC=C(N4CCN(C(CNC5=CC=C(S(=O)(NC(C6=CC=C(N7CCN(CC8=C(C9=CC=C(Cl)C=C9)CC(C)(C)CC8)CC7)C=C6OC%10=CN=C(NC=C%11)C%11=C%10)=O)=O)C=C5[N+]([O-])=O)=O)CC4)C(OC)=C3)N

Molecular Formula

C64H73ClN14O10S

Molecular Weight

1265.87

References & Citations

[1]Christopher C Goodis, et al. The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN) and the FLT3 inhibitor gilteritinib (GIL) is more active in acute myeloid leukemia cells than novel polypharmacologic BCL-2/FLT3 VEN–GIL hybrid single-molecule inhibitors. Eur J Med Chem. 2024 Dec 22:285:117190.